Developing an inhaled antibody therapy for a common respiratory virus in children
Official title: IND-enabling development for IN-003, an inhaled mAb therapy against human metapneumovirus infection
Funded at Inhalon Biopharma, INC. · NIH-11089428 · Data updated 2026-11-12
This study is testing a new inhaled treatment for young children with human metapneumovirus (MPV), a common cause of respiratory infections, to see if delivering a special medicine directly to their lungs can help them feel better faster.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Inhalon Biopharma, INC. NIH-funded |
| Lab location | 1 site (Morrisville, UNITED STATES) |
| Project start | May 15, 2024 |
| Project end | April 30, 2027 |
| Funding year | 2025 |
| Award (this year) | $1,024,879 |
| NIH project number | 5R44AI181347-02 |
| Project ID | NIH-11089428 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are infants and young children under 11 years old who are at risk of lower respiratory tract infections caused by human metapneumovirus.
✕Less likely to help
Patients who are not affected by human metapneumovirus or those who are older than 11 years may not benefit from this research.
What this research studies
This research focuses on creating a new inhaled monoclonal antibody (mAb) therapy to treat human metapneumovirus (MPV), which is a leading cause of respiratory infections in infants and young children. The approach involves delivering high concentrations of the mAb directly to the respiratory tract using handheld nebulizers, allowing for quick and effective treatment. This method aims to overcome the limitations of traditional antiviral therapies that are not effective for MPV. By targeting the site of infection directly, the therapy hopes to provide a safe and effective option for patients suffering from MPV infections.
Why it matters
Potential benefit: If successful, this research could provide a much-needed effective treatment for infants and young children suffering from MPV infections.
How similar studies have gone: Previous research has shown promise in using inhaled monoclonal antibodies for respiratory infections, indicating potential success for this novel approach.
Where this research is happening
-
Inhalon Biopharma, INC.
Morrisville, United States Active
Researchers
- Principal investigator: Hutchins, Jeff T — Inhalon Biopharma, INC.
- Study coordinator: Hutchins, Jeff T
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.